PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28499726-8	2017	These results suggest that donepezil inhibits the inflammatory response induced by bradykinin via nAChR and PI3K-Akt pathway in astrocytes.	Donepezil	27-36	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	98-103	
11261808-4	2000	This nAChR-sensitizing action is not a common property of all, or most, AChE inhibitors, as is shown by the absence of this effect for other therapeutically applied AChE inhibitors including tacrine, metrifonate, rivastigmine and donepezil.	Donepezil	230-239	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	5-10	
26315944-6	2015	We also found that the increase in the number of oligodendrocytes observed following donepezil treatment was significantly inhibited by the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine, but not by the muscarinic acetylcholine receptor antagonist scopolamine.	Donepezil	85-94	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	140-172	
26315944-6	2015	We also found that the increase in the number of oligodendrocytes observed following donepezil treatment was significantly inhibited by the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine, but not by the muscarinic acetylcholine receptor antagonist scopolamine.	Donepezil	85-94	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	174-179	
12649296-3	2003	The other presently approved AD drugs, donepezil and rivastigmine, are devoid of the nicotinic APL action; at micromolar concentrations they also block nAChR activity.	Donepezil	39-48	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	152-157